Gemcitabine
Product Images NDC 16729-423

Gemcitabine Injection is a medicine that comes in a vial containing 15 mL of the solution for intravenous infusion. Each vial has 159 gemcitabine (equivalent to 1707 g gemcitabine hydrochloride USP), PEG300, 375 3 Popyene Giyco, 225, and Sodium Hydron, 240 and deryrated acono, asto 15l Hysrochon ace and/or sodum hyronie, and may have been adied to dustpt. Storage should be maintained at a temperature of 3 20°C 025°C. The medicine must be discarded 28 days after initial puncture and should not be refrigerated. For further information, see the prescribing information for the complete dilution information and usual adult doses. However, the text mentions "Keep area blark & varich ree for overcoding Lot and EXP" which suggests that the text is a label, and therefore it should be read cautiously and with knowledge.*

NDC 16729-423-33 is a prescription drug with dosing and usage instructions provided in the accompanying prescribing information. Gemcitabine injection can be stored at room temperature between 20°C to 25°C (68°F to 77°F) without refrigeration. The vial should be discarded within 28 days of the initial puncture, and the injection should be kept in a varnish-free and controlled environment. The drug must be diluted before administering through Intravenous Infusion Only. The drug should not be used after the expiration date. The drug is manufactured by Intas Pharmaceuticals Limited situated in Anmedabad, India, and batch coding and data matrix pyram are provided.*

This is a product description for Gemcitabine Injection, a sterile multi-dose vial with 100mg/mL for intravenous infusion only after dilution. It needs to be discarded 28 days after initial puncture and should not be refrigerated. The storage temperature should be controlled at room temperature. It is manufactured by Pharmaceuticals Limited.*

This medication, Gemcitabine, is available in a multiple-dose vial of 10mL and is for intravenous infusion only. It should be stored at controlled room temperature and discarded 28 days after initial puncture. It should not be refrigerated and must be diluted before use. The dosage and usage information can be found in the prescribing information, which accompanies the medication. Mfd. for Accord Healthcare Inc., Durham, NC. Mfd. by Intas Pharmaceuticals Limited, Ahmedabad-382210, India.*

This is a medical label for Gemcitabine Injection, a cytotoxic agent used for intravenous infusion. The label provides the dosage for adults, the storage instructions including not refrigerating it, the discard date after initial puncture, and dilution information. The manufacturer is Acsord Healthcare and Intas Pharmaceuticals Ltd.*

This is a description of Gemcitabine Injection, a medication that must be diluted and used for intravenous infusion only. The medication is available as a 20 mL sterile multiple-dose vial and each vial contains 100 mg/mL of Gemcitabine. The vial must be discarded 28 days after initial puncture. The usual dosage and prescribing information can be obtained from the packaging. The medication should not be refrigerated and should be stored in a cool, dry place with the lot and expiration information visible and unobstructed. The medication is manufactured by Intas Pharmaceuticals Limited in India.*

Gemcitabine is a medication used for intravenous infusion only and must be diluted before use. It is stored at controlled room temperature and should not be refrigerated. The medication comes in a multiple-dose vial and should be discarded 28 days after initial puncture. Dosage and use information can be found in the accompanying prescribing information. The medication is manufactured by Intas Pharmaceuticals Limited in India and distributed for Accord Healthcare Inc in Durham, NC. Lot and expiration information can be found on the packaging.*

This text presents data on the median time for documented disease progression for two different chemotherapy treatments: Gemcitabine/Paclitaxel and Paclitaxel alone. According to the text, the median time for documented disease progression was 5.2 months for Gemcitabine/Paclitaxel and 2.9 months for Paclitaxel alone. A statistical analysis showed a significant difference between the two treatments with a p-value of less than 0.0001. The text also includes a chart displaying the time to documented disease progression for each treatment.*

This appears to be a table showing the median survival time (in months) for two different treatments for a medical condition. The treatments are listed as "Gem/Cis" and "cis" which may refer to chemotherapy. The median survival times listed are 9.0 months for Gem/Cis and 7.6 months for cis. The text "probat" and "Survival" do not seem to be relevant to the information provided.*

This is a graph that shows the progression-free survival probability of two chemotherapy treatments (Gemcitabine /Carboplatin and Carboplatin alone) for a group of 178 participants. The x-axis represents the months of progression-free survival, and the y-axis represents the probability. The graph displays the median progression-free survival for each treatment, 8.6 months for Gemcitabine/Carboplatin and 5.8 months for Carboplatin alone, as well as the log-rank probability value of 0.0038.*